Related Experiment Videos
Haemodynamic effects of captopril in acute left ventricular failure complicating myocardial infarction
Insights
Captopril effectively reduced pulmonary capillary wedge pressure and improved hemodynamics in patients with acute myocardial infarction and left ventricular failure. This suggests angiotensin II reduction benefits heart failure complicating heart attacks.
Area of Science:
- Cardiology
- Pharmacology
Background:
- The renin-angiotensin system plays a crucial role in the hemodynamics of acute myocardial infarction.
- Left ventricular failure is a common and serious complication of myocardial infarction.
Purpose of the Study:
- To evaluate the hemodynamic effects of captopril in patients experiencing acute myocardial infarction with left ventricular failure.
- To assess the impact of reducing angiotensin II levels on cardiac function in this patient population.
Main Methods:
- Nine patients with acute myocardial infarction and left ventricular failure were administered repeated low doses of captopril.
- Hemodynamic parameters, including right atrial pressure, pulmonary arterial pressure, and pulmonary capillary wedge pressure, were monitored.
- Plasma angiotensin II levels were measured before and after captopril administration.
Main Results:
- Captopril significantly reduced right atrial pressure, pulmonary arterial pressure, and pulmonary capillary wedge pressure.
- Systemic vascular resistance and mean arterial pressure decreased, while cardiac output remained relatively stable.
- Plasma angiotensin II levels were substantially reduced in all patients, irrespective of baseline levels or diuretic use.
Conclusions:
- Reduction of angiotensin II with captopril demonstrates beneficial hemodynamic effects in heart failure secondary to acute myocardial infarction.
- Captopril offers a promising therapeutic strategy for managing acute myocardial infarction complicated by left ventricular failure.
Abstract:
Activation of the renin-angiotensin system in acute myocardial infarction may have important haemodynamic consequences. The effects of captopril were assessed in nine patients with acute left ventricular failure complicating myocardial infarction. Plasma angiotensin II was elevated at 16.8 (3.6) pmol/l (mean [SE]) including high levels in three of four patients in the absence of any previous therapy, including diuretics. Repeated low doses of captopril were administered to reduce pulmonary capillary wedge pressure less than 14 mm Hg or to a maximum total dose of 25 mg. Right atrial pressure fell from 12.4 (0.9) to 9.4 (0.7) mm Hg p less than 0.001, pulmonary arterial pressure from 32.7 (3) to 26.4 (2.2) p = 0.01, and pulmonary capillary wedge pressure from 25.7 (2.9) to 19.9 (2.2) p = 0.01. Despite a fall in systemic vascular resistance from 1,540 (110) to 1,330 (76) dyn/s/cm5, and mean arterial pressure from 84.8 (3.9) to 76.7 (2.7) p = 0.001, changes in cardiac output were small: 3.8 (0.3) to 4.2 (0.3) NS. Angiotensin II fell in all patients even after only 3.125 mg to a mean of 3.6 (1.0). These improvements occurred whether basal angiotensin II was elevated or normal, and in the presence or absence of diuretic therapy. At 24 hours, seven patients received captopril in the maximum titrated dose of the previous day. Haemodynamic changes at one hour were of similar magnitude to those during incremental dosing. These results suggest that reduction of angiotensin II exerts beneficial haemodynamic effects in heart failure complicating acute myocardial infarction.